We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Personal Cell Analysis System Monitors Treatment of HIV/AIDS

By LabMedica International staff writers
Posted on 27 Oct 2008
A new system, based on the personal cell analysis platform (PCA) platform, is designed for diagnosis and monitoring human immunodeficiency virus infections.

Dubbed the AutoCD4/CD4% system, it includes new automated gating and acquisition software and a single antibody cocktail. More...
Designed specifically to meet the needs and challenges of a broad population of users, the easy-to-use software allows operators with minimal technical expertise to monitor a patient's T-lymphocytes accurately and effortlessly.

From a single assay, a technician can get a patient's CD4 count, total lymphocyte count, and CD4% value with only 10 µl of whole blood, and acquire results with just one click of a button. The CD4% value is particularly critical for pediatric patients.

The new software also includes an error detection feature and easy-to-read results in the form of individual patient as well as summary reports. These features help ensure reproducible, high quality test results from every sample.

Guava Technologies, Inc. (Stamford, UK) launched Guava AutoCD4/CD4% system with the expectation that it will help fight the global AIDS pandemic. "Access to appropriate diagnostic tools is crucial in the battle against HIV/AIDS, and we are committed to developing our clinical cell analysis technology so that it is truly accessible to those who need it anywhere in the world," said Larry Bruder, president & CEO of Guava Technologies. "We designed our AutoCD4/CD4% system so that any healthcare professional-even one without prior experience with flow cytometry-can get accurate and reliable test results every time."

The patented microcapillary design eliminates the need for complicated fluidics making Guava Instruments ideally suited for use anywhere in the world, even in remote regions. They are more compact and have fewer moving parts than most traditional flow cytometers. They also accommodate smaller sample volumes, have lower reagent demands, and generate less waste. Guava Software guides the user through whatever procedure is being conducted, whether it is an assay, instrument setup, or routine maintenance.

Related Links:
Guava Technologies



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.